|
- HIV prevention drug lenacapavir approved by FDA as twice-yearly . . .
Why FDA approval of new HIV prevention drug is a big deal The U S Food and Drug Administration has approved the drug lenacapavir as a twice-yearly injection to prevent HIV
- Yeztugo Lenacapavir Is Now the First and Only FDA Approved HIV . . .
FOSTER CITY, Calif -- (BUSINESS WIRE)-- Gilead Sciences, Inc (Nasdaq: GILD) today announced that the U S Food and Drug Administration (FDA) has approved Yeztugo ® (lenacapavir)—the company’s injectable HIV-1 capsid inhibitor—as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg, making it the first and only
- FDA approves twice-a-year injection for HIV prevention - CNN
A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug Administration to be used to prevent HIV
- FDA approves powerful HIV prevention drug: What to know about Yeztugo
The twice-yearly injectable drug’s potential could be compromised by the Trump administration’s dramatic cuts to HIV-prevention infrastructure in the U S
- FDA Approves First Twice-a-Year HIV Prevention Shot, Yeztugo
via HealthDay FRIDAY, June 20, 2025 — A new shot to prevent HIV infection has just been approved — and it only needs to be taken twice a year On Wednesday, the U S Food and Drug Administration (FDA) approved lenacapavir, a long-acting injection that was shown to be nearly 100% effective in clinical trials Made by Gilead Sciences and sold under the name Yeztugo, the drug gives people a
- FDA approves new twice-yearly HIV shot in bid to end epidemic
The Food and Drug Administration has approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show prevents new infections The drug will
- For HIV AIDS, FDA approves next best thing to a vaccine | STAT
HIV protection with just two shots a year: FDA approves Gilead drug Lenacapavir, to be sold as Yeztugo, has potential to bring AIDS pandemic to heel but faces Trump-era obstacles
- FDA approves twice-yearly injection for HIV prevention
FDA approves Yeztugo as the first U S twice-yearly injectable for HIV prevention, showing 99 9% efficacy and broad access for all patients
|
|
|